---
schema_version: "secwatch.filing_event.v1"
accession: "0001100682-22-000037"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2022-12-06T23:59:59+00:00"
generated_at: "2026-06-21T08:35:27.370821+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Charles River Labs appoints Dr. Craig B. Thompson to Board

## Summary
- Board expanded from 10 to 11; Dr. Thompson appointed effective Dec. 5, 2022.
- Appointed to Science & Technology Committee and Strategic Planning & Capital Allocation Committee.
- Initial pro-rata equity award valued at $255,500 (50% RSUs, 50% stock options).
- Thompson is former CEO of Memorial Sloan Kettering (2010-2022) and current Regeneron board member.

## SEC filing metadata
- accession: 0001100682-22-000037
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2022-12-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000110068222000037/0001100682-22-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000110068222000037/crl-20221205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001100682-22-000037
- JSON: https://secwatch.observer/filing/0001100682-22-000037.json
- Plain text: https://secwatch.observer/filing/0001100682-22-000037.txt

## Key facts
- Executive change
  Craig B. Thompson was appointed as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
  - Action: appointed
  - Role: Director
  source text: Following the size increase of the Board, the Board filled the vacancy and appointed Dr. Craig B. Thompson to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100682/000110068222000037/0001100682-22-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.